Objectives: The physical compatibility and chemical stability of ranitidine hydrochloride injectable solutions and oral syrup were studied to define beyond-use dates (BUDs). Methods: Ranitidine hydrochloride injectable solutions of 25 mg/mL packaged in glass vials and 5 mg/mL in polypropylene (PP) syringes were prepared in triplicate. Samples were refrigerated and protected from light (PFL) or stored at 25°C and either exposed to light (ETL) or PFL. Ranitidine hydrochloride oral syrup 15 mg/mL in unit-dose amber PP syringes were prepared in triplicate and then kept at 25°C. Samples were collected at days 0, 7, 14, 28, 56, and 91. Additional samples were collected at 6 months and at 6, 9, and 12 months for the 25 mg/mL solution and oral syrup, respectively. Physical parameters of pH, clarity, and color were obtained at each collection time. A validated stability-indicating high-performance liquid chromatography (HPLC) method was used to determine the chemical stability. Results: Formulations had no significant change in pH or clarity. Although some samples yellowed, this was not associated with a decrease in concentration. The 25 mg/mL solution remained above 98.6% for 6 months, whereas the 5 mg/mL solution remained above 93.5% for 91 days under all storage conditions. At 25°C, the oral syrup retained greater than 98.8% for 12 months. Conclusions: The ranitidine hydrochloride injectable solutions were stable for 6 months and 91 days under the 3 storage conditions, respectively, for the 25 mg/mL solution in glass vials and 5 mg/mL solution in PP syringes. The 15 mg/mL oral syrup in unit-dose amber PP syringes was stable for 12 months at 25°C and PFL.
Introduction
Ranitidine is a histamine H2-receptor antagonist that acts by antagonizing histamine at gastric H2-receptor sites. Ranitidine inhibits both basal gastric secretion and gastric acid secretion induced by histamine, pentagastrin, and other secretagogues. 1, 2 Ranitidine is used for many different indications including gastroesophageal reflux disease and the prophylaxis of stress ulceration in critically ill patients. [1] [2] [3] Review of the literature found 8 articles that reported the stability of ranitidine hydrochloride injectable solutions in polyvinyl chloride (PVC) bags, polypropylene (PP) syringes, glass vials, and glass ampoules. [4] [5] [6] [7] [8] [9] [10] [11] Six of the studies involved ranitidine hydrochloride injection packaged in PVC bags with concentrations ranging 0.05 to 2 mg/mL in either normal saline (NS), 5% dextrose in water (D5W), 10% dextrose in water, 5% dextrose with 0.45% sodium chloride, or 5% dextrose with lactated Ringer's. [4] [5] [6] [7] [8] [9] The longest reported stability in PVC bags was for 92 days at 4°C in NS or D5W. One study, involved ranitidine hydrochloride stored in PP syringes at 2.5 mg/mL when diluted with sterile water for injection (SWI), found the solution was stable for up to 94 days (72 hours at 22°C then 91 days at 4°C). 10 Two studies assessed the stability of ranitidine hydrochloride in glass vials and ampoules. 10, 11 Glass vials of 2.5 mg/mL ranitidine hydrochloride in SWI were stable for 91 days at 4°C. In brown glass ampoules, ranitidine hydrochloride 25 mg/mL in SWI was stable for 12 months at 25°C and 3 months at 55°C.
A study assessing ranitidine hydrochloride oral syrup 15 mg/mL packaged in amber glass bottles found the syrup to be stable for 13 (40°C) and 52 (25°C) weeks. 12 Due to the lack of stability data for ranitidine at the concentrations and packaging formats used at our institute, this study was initiated to evaluate the physical compatibility and chemical stability of ranitidine hydrochloride. Commercially available injectable solution, 25 mg/mL, was repackaged in glass vials or diluted to 5 mg/mL with NS in PP syringes and stored at either 5°C and protected from light (PFL) or 25°C and exposed to light (ETL) or PFL. Ranitidine oral syrup, 15 mg/mL, in unit-dose amber PP syringes was also studied at 25°C. Chemical stability of the solutions was assessed using a validated stability-indicating high-performance liquid chromatography (HPLC) method. Determining this stability will establish the beyond-use dates (BUDs) and help to potentially prevent the wastage of materials and labor, and optimize the storage conditions.
Methodology

Materials
Ranitidine hydrochloride 25 mg/mL injectable solution (GlaxoSmithKline, Mississauga, Ontario, Canada) and ranitidine hydrochloride 15 mg/mL commercially available syrup (Teva Canada, Montreal, Quebec, Canada) were used to compound the test solutions. NS (Baxter Inc, Mississauga, Ontario, Canada) was used to dilute the ranitidine to 5 mg/ mL. Solutions were stored in either glass vials (Allergy Laboratories, Oklahoma City, Oklahoma), PP syringes (Becton Dickinson and Company, Franklin Lakes, New Jersey), or amber PP syringes (Medisca Inc, Saint-Laurent, Quebec, Canada). Ranitidine hydrochloride USP (United States Pharmacopeia, Rockville, Maryland), caffeine citrate USP (Professional Compounding Centers of America, London, Ontario, Canada), and ranitidine-related compound C (United States Pharmacopeia) powders were used to compound reference solutions. All other chemicals used were HPLC or American Chemical Society grade.
Sample Preparation
Ranitidine hydrochloride 25 mg/mL injectable solution samples were prepared, aseptically, by transferring 2.2 mL of solution into each glass vial. Samples were collected, in triplicate, and frozen at −70°C, to be analyzed at a later date, on days 0, 7, 14, 28, 56, 91, and at 6 months. During the study, vials were stored at either 5°C and PFL or 25°C and ETL or PFL.
Ranitidine hydrochloride 25 mg/mL injectable solution was diluted, aseptically, with NS to 5 mg/mL and packaged in PP syringes. The samples (5 mL) were drawn from 3 syringes at days 0, 7, 14, 28, 56, and 91. Samples were transferred into sealed glass vials and then frozen at −70°C to be analyzed at a later date. After day 0, samples were collected from 3 syringes which had been stored at either 5°C and PFL or 25°C and ETL or PFL.
Ranitidine hydrochloride oral syrup, 5 mL of 15 mg/mL, was transferred to unit-dose 10-mL PP amber oral syringes. Contents (5 mL) of 3 syringes were collected on days 0, 7, 14, 28, 56, and 91 and at 6, 9, and 12 months. The samples were transferred into amber glass bottles, sealed with a screw-on cap, and then frozen at −70°C to be analyzed at a later date. The syringes were stored at 25°C for the duration of the study.
On each day of analysis, samples from one storage condition were thawed at room temperature for approximately 1 hour prior to HPLC batch analysis. Injectable PP syringe samples were prepared using 20 µL of 5 mg/mL ranitidine, 50 µL of 1 mg/mL caffeine, and 930 µL of methanol 30%. Injectable glass vial samples contained 20 µL of 25 mg/mL ranitidine, 75 µL of 1 mg/mL caffeine, and 1405 µL of methanol (MeOH) 30%. Oral amber syringe samples used 20 µL of 15 mg/mL ranitidine, 75 µL of 1 mg/mL caffeine, and 1405 µL of MeOH 30%. Each sample was assayed in duplicate.
Physical Compatibility
Clarity and color change were determined by visual inspection with the aid of a 4× illuminated magnifying glass and a hexadecimal color chart. 13 A calibrated pH meter (Fisher Scientific Model Accumet 25 pH meter; Fisher Scientific Company, Nepean, Canada) was used to determine the pH of the solutions.
Chromatographic Conditions
Samples were analyzed using an HPLC system that consisted of a column packed with a stationary phase containing C The HPLC method was developed by modifying the USP-NF assay method for ranitidine injection from 2014. 14 The following changes to the USP-NF ranitidine injection HPLC methodology were made; mobile phase was increased to 25% MeOH in 0.1-M ammonium acetate, mobile phase pH was adjusted to approximately 6.9, flow rate was decreased to 1.0 mL/min, the HPLC detector was set to 230 nm, and caffeine citrate was used as an internal standard.
Method Validation
Forced degradation was used to assess the specificity of our stability-indicating method. A stock solution of ranitidine 1 mg/ mL was prepared. Ranitidine solutions were exposed to acidic conditions (concentrated hydrochloric acid, pH = 1.7), alkaline conditions (sodium hydroxide 5 N, pH = 11.7), an oxidizing agent (30% hydrogen peroxide), and ultraviolet (UV) light. Multiwavelength (230 and 280 nm) and UV spectra (200-350 nm) analyses were used to compare ranitidine peaks from all degradation samples to a USP reference material peak to confirm purity. USP reference ranitidine-related compound C, a known by-product of ranitidine degradation, and ranitidine were also analyzed to confirm the separation of these 2 peaks.
Interday variation was determined using results for slope and r 2 , and area ratio of a standard solution on 5 separate days. Intraday variation was performed by analysis of 5 replicate injections at 0, 20, and 36 hours. Analysis of a recovery solution of known concentration on 5 separate days was used to determine the method accuracy. The limit of quantification (LOQ) was found by analyzing increasingly more dilute standard solutions.
Results
The ranitidine degraded fastest under oxidizing conditions, having only 22.1% remaining after 4 hours ( Figure 1C ). As expected, ranitidine degraded the slowest under acidic conditions ( Figure 1A) . The most degradation occurred in the sample exposed to the intense UV light with almost all of the ranitidine degrading after 14 days of exposure. All the degradation products eluted faster than the patent peak. No degradation products were found to interfere with the ranitidine or internal standard peaks. The ranitidine-related compound C eluted at 4.5 minutes so did not interfere with either the ranitidine or internal standard peaks.
All ranitidine peaks were confirmed to be pure using multiwavelength and UV spectra analyses (Purity Index > 0.99).
Comparison of the UV spectra of a ranitidine reference sample with the UV spectra of ranitidine peaks in degradation samples gave a correlation coefficient of 0.9995 or greater.
The intraday analysis found a 0.2% variation over 36 hours. The interday analysis determined the coefficient of variances of the slope of the standard curves to be 1.93, the area ratio was 0.68, and r 2 was 0.16. The standard curves were linear over the range of 0.01 to 0.2 mg/mL and 0.025 to 0.4 mg/mL of ranitidine. The average recovery was 102.4 ± 0.74%. The LOQ study showed the lowest amount of ranitidine that could be detected while maintaining a linear relationship was 10 ng.
The pH of ranitidine injectable solutions and oral syrup remained consistent for samples under each storage condition. The ranitidine solutions were initially colorless to slightly yellow (hexadecimal color# FFFFF0). 13 Color change did occur for some samples over time, turning more yellow. The change in color was most apparent with higher concentrations of ranitidine after 6 months at 25°C and in samples exposed to light (hexadecimal color# FCF75E).
13 Injectable solutions and oral syrup remained clear with no precipitate being observed under a 4× magnifying glass at all time points.
The ranitidine stability results are presented in Tables 1 to 3 . The 25 mg/mL injectable solution had no less than 98.6 ± 0.6%, 99.3 ± 1.0%, and 98.6 ± 1.21% remaining after 6 months when refrigerated and PFL, or 25°C and PFL or ETL, respectively. The 5 mg/mL injectable solution after 91 days had at least 93.5 ± 1.7%, 97.0 ± 0.8%, and 96.3 ± 1.0% remaining when refrigerated and PFL, and ETL or PFL at 25°C, respectively. The 15 mg/mL oral syrup had no less than 98.8 ± 1.1% of the initial concentration remaining at 12 months when stored at 25°C in amber PP syringes.
Discussion
The physical compatibility data were compared with stability analysis to try to determine any correlation between degradation and physical changes of ranitidine. The results from the pH study show no significant change in pH for samples over the course of the study. The results from the color study showed an increased yellowing of the samples over time, in particular those at higher concentrations and those exposed to light. This would be expected as there is a 5× increase in the concentration of the drug which would lead to 5× more color intensity. However, neither change in color was associated with a decrease in concentration. Solutions remained clear with no precipitate forming, which suggests that the ranitidine and degradation products remained in solution throughout the testing.
The 25 mg/mL injectable ranitidine solution in glass vials was found to be stable for 6 months; however, the refrigerated day 7 samples results are erroneously high, due to pipetting errors ( Table 1 ). The 5 mg/mL injectable ranitidine solution in PP syringes was stable for 91 days, at both 25°C and under refrigeration, based on stability data from this study. These injectable solutions do not need to be protected from light, because exposure to light was not found to change the stability of the ranitidine. Our results are similar to the literature values so the type of diluent and concentration does not seem to affect the stability. The 15 mg/mL ranitidine syrup packaged in oral amber PP syringes was stable for 12 months at 25°C. These results are the same as the literature results for ranitidine syrup packaged in amber glass bottles, so the type of packaging material does not seem to affect the BUD of the product. There was difficulty accurately pipetting the 15 mg/mL oral syrup due to its viscosity. To improve consistency and accuracy, a reverse pipetting technique was used. The samples were also each weighed to ensure the technique's effectiveness. As the syrup was packaged in amber syringes, it was unexpected that the solution changed color over time. This is possibly due to a specific spectrum of light being able to penetrate the amber syringe; however, the color change did not correlate with a loss in potency.
Conclusion
The BUDs for several ranitidine formulations were determined. The 25 mg/mL injectable solution in glass vials was stable for 6 months when refrigerated and PFL, or either ETL or PFL at 25°C. The 5 mg/mL injectable solution in PP syringes remained stable for 91 days when refrigerated and PFL, or 25°C and either ETL or PFL. The 15 mg/mL oral syrup was found to be stable in oral amber syringes at 25°C for 12 months. Determining this stability should help to prevent the wastage of materials and labor, optimize the storage conditions, and address the concern over whether the products need to be protected from light or not. These BUDs are based solely on physical compatibility and chemical stability of ranitidine under the conditions studied as microbial contamination was not addressed.
